

EXHIBIT 1032

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : To be determined (TBD)
(Reissue application of U.S. Patent No. 9,884,885)
1st Named Inventor : Suresh C. Srivastava
Filed : Herewith
TC/A.U. :
Examiner :

Docket Number : 4925-0123-REI
Customer No. : 6449
Confirmation No. :

MAIL STOP REISSUE

Commissioner for Patents
P.O. Box 1450

REISSUE PRELIMINARY AMENDMENT

Before examination of the instant application for reissue of U.S. Patent No.
9,884,885, please amend the above-identified reissue patent application as follows:

Amendments to the Specification begin on page 2 of this paper.


Amendments to the Claims begin on page 5 of this paper.

Remarks begin on page 15 of this paper.

AMENDMENTS TO THE SPECIFICATION:

Pursuant to 37 C.F.R. § 1.173(b)(1) and M.P.E.P. § 1453(I), please revise the paragraphs in col. 17, l. 59 to col. 18, l. 45 as follows:

The invention provides a novel method of RNA synthesis utilizing N-2-acetyl guanosine-5'-DMT-2'-TBDMS-protected nucleoside phosphoramidite and other nucleoside phosphoramidites outlined in Formula 1 below. The synthetic route that has been developed allows obtaining desired nucleosides without any contamination with unwanted impurities. The N-2-acetyl protected guanosine nucleosides and other N-2 acetyl protected nucleosides having various 2'-protecting group discussed or 2'-modification, such as 2'-fluoro or 2'-amino groups can be combined with cyanoethyl phosphate protecting group and utilized in high purity RNA synthesis




Formula 1

Where B = a) Adenine (N-bz), b) Cytosine (N-acetyl), c) Guanine (N-acetyl), d) 5-methyl cytosine(N-Fmoc), e) 5- bromocytidine (N-Fmoc), i) 5-iodo cytosine(N-Fmoc), j) 5- fluorocytosine (N-Fmoc), k) 2,6-diaminopurine (N-Fmoc), l) 2-amino purine (N-Fmoc), Z= Oxygen & W is H,; Z=Oxygen and W= tButyldimethyl silyl, TOM (triisopropylloxymethylene), acetal levulinyl ester (ALE), pivaloyloxy;

cyanoethylmethylene (CEM); dithiomethylene (DTM); Z= oxygen and W is methyl and other higher alkyls, alkenes and alkynes; Z=W= ribo Fluorine; Z=W=ara fluorine; Z=amino, W= amino protecting group; X = a) cyanoethyl-dialkyl phosphoramidite.

The nucleic base in our invention is protected with N-2 acetyl guanosine (Acetyl; Ac). The solid support having protected nucleosides containing 5'-DMT group and 3' terminus is attached to solid support (Formula 2).



Where B=Adenine (N-bz), Cytosine (N-acetyl), Guanine (N-acetyl), 5-methyl cytosine (N-Fmoc), 5-bromocytidine (N-Fmoc), 5-iodo cytosine (N-Fmoc), 5-fluorocytosine (N-Fmoc), 2,6-diaminopurine (N-Fmoc), or 2-amino purine (N-Fmoc);


Z=succinimido long chain attached to a solid support, hydroquinone succinimido long chain spacer attached to solid support, or oxalyl amido long chain spacer attached to solid support;

W=Oxygen & R is H; or, W=Oxygen and R=tButyldimethyl silyl, TOM

(triisopropylloxymethylene), acetal levulinyl ester (ALE), pivaloyloxy; cyanoethylmethylene (CEM); or dithiomethylene (DTM); or, W=oxygen and R is methyl or other higher alkyl, alkene or alkyne; or, W=ribo Fluorine, where the fluoro radical points downward in ribo

configuration and R is absent; or W=ara fluorine, where the fluoro radical points upward in ara configuration (Formula 3) and R is absent; or, W=amino, and R=amino protecting group.


(Formula 3)



AMENDMENTS TO THE CLAIMS:

Please amend claims 1, 4, and 5, and add new claims 6-65, set forth below, with markings in compliance with 37 C.F.R. § 1.173(d).

Claim 1 (Amended). Derivatized nucleoside and phosphoramidite of general formula 1,




Formula 1

where B is selected from the group consisting of Guanine-N-acetyl, adenine-N-acetyl, [cytosine-N-acetyl,]cytosine-N-isobutyryl, 5-methyl cytosine-N-acetyl, and 5-methyl cytosine-N-isobutyryl;

Z is Oxygen and W is methyl; and

X is cyanoethyl dialkyl phosphoramidite.

Claim 4 (Amended). Derivatized nucleosides, succinates and solid supports of general formula 2,




(Formula 2)

wherein, B is selected from the group consisting of Guanine-N-acetyl, adenine-N-acetyl, [cytosine-N-acetyl,] cytosine-N-isobutyryl, 5-methyl cytosine-N-acetyl, and 5-methyl cytosine-N-isobutyryl;

W is Oxygen and R is selected from the group consisting of t-Butyldimethyl silyl, acetal levuliny ester (ALE), pivaloyloxy, cyanoethylmethylene (CEM), dithiomethylene (DTM)); and

Z is C(O)-M-C(O)—NH, where M is selected from the group consisting of succinyl, oxalyl, and hydroquinolynyl, and NH is capable of being attached to a solid support with a spacer selected from the group consisting of C1-C20 alkyl, ethyloxyglycol, and a combination of alkyl and ethyleneglycoxy.

Claim 5 (Amended). Derivatized nucleosides, succinates and solid supports of general formula 2,



wherein B is selected from the group consisting of Guanine-N-acetyl, adenine-N-acetyl, [cytosine-N-acetyl, cytosine-N-isobutyryl,]5-methyl cytosine-N-acetyl, and 5-methyl cytosine-N-isobutyryl;

W is Oxygen and R is methyl; and

Z is C(O)-M-C(O)-NH, where M is selected from the group consisting of succinyl, oxalyl, and hydroquinolynyl, and NH is capable of being attached to a solid support with a

spacer selected from the group consisting of C1-C20 alkyl, ethyloxyglycol, and a combination of alkyl and ethyleneglycoxy.

Claim 6 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 1, wherein B is guanine-N-acetyl.

Claim 7 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 1, wherein B is adenine-N-acetyl.

Claim 8 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 1, wherein B is cytosine-N-isobutyryl.

Claim 9 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 1, wherein B is 5-methyl cytosine-N-acetyl.

Claim 10 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 1, wherein B is 5-methyl cytosine-N-isobutyryl.

Claim 11 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 2, wherein B is guanine-N-acetyl.

Claim 12 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 11, wherein Z is ribo fluoro.

Claim 13 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 11, wherein Z is ara fluoro.

Claim 14 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 2, wherein B is adenine-N-acetyl.

Claim 15 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 14, wherein Z is ribo fluoro.

Claim 16 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 14, wherein Z is ara fluoro.

Claim 17 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 2, wherein Z is ribo fluoro.

Claim 18 (New). The derivatized nucleoside and phosphoramidite of general formula 1 according to claim 2, wherein Z is ara fluoro.

Claim 19 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 3, wherein B is guanine-N-acetyl.

Claim 20 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 19, wherein W is ribo fluoro.

Claim 21 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 19, wherein W is ara fluoro.

Claim 22 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 3, wherein B is adenine-N-acetyl.

Claim 23 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 22, wherein W is ribo fluoro.

Claim 24 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 22, wherein W is ara fluoro.

Claim 25 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 3, wherein W is ribo fluoro.

Claim 26 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 3, wherein W is ara fluoro.

Claim 27 (New). The derivatized nucleosides, succinates and solids support of general formula 2 according to claim 4, wherein B is guanine-N-acetyl.

Claim 28 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 27, wherein R is t-Butyldimethyl silyl.

Claim 29 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 27, wherein R is ALE.

Claim 30 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 27, wherein R is pivaloyloxy.

Claim 31 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 27, wherein R is CEM.

Claim 32 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 27, wherein R is DTM.

Claim 33 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 4, wherein B is adenine-N-acetyl.

Claim 34 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 32, wherein R is t-Butyldimethyl silyl.

Claim 35 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 32, wherein R is ALE.

Claim 36 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 27, wherein R is pivaloyloxy.

Claim 37 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 32, wherein R is CEM.

Claim 38 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 32, wherein R is DTM.

Claim 39 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 4, wherein B is cytosine-N-isobutyryl.

Claim 40 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 37, wherein R is t-Butyldimethyl silyl.

Claim 41 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 37, wherein R is ALE.

Claim 42 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 27, wherein R is pivaloyloxy.

Claim 43 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 37, wherein R is CEM.

Claim 44 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 37, wherein R is DTM.

Claim 45 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 4, wherein B is 5-methyl cytosine-N-acetyl.

Claim 46 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 42, wherein R is t-Butyldimethyl silyl.

Claim 47 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 42, wherein R is ALE.

Claim 48 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 27, wherein R is pivaloyloxy.

Claim 49 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 42, wherein R is CEM.

Claim 50 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 42, wherein R is DTM.

Claim 51 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 4, wherein B is 5-methyl cytosine-N-isobutyryl.

Claim 52 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 47, wherein R is t-Butyldimethyl silyl.

Claim 53 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 47, wherein R is ALE.

Claim 54 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 27, wherein R is pivaloyloxy.

Claim 55 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 47, wherein R is CEM.

Claim 56 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 47, wherein R is DTM.

Claim 57 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 4, wherein R is t-Butyldimethyl silyl.

Claim 58 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 4, wherein R is ALE.

Claim 59 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 27, wherein R is pivaloyloxy.

Claim 60 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 4, wherein R is CEM.

Claim 61 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 4, wherein R is DTM.

Claim 62 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 5, wherein B is guanine-N-acetyl.

Claim 63 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 5, wherein B is adenine-N-acetyl.

Claim 64(New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 5, wherein B is 5-methyl cytosine-N-acetyl.

Claim 65 (New). The derivatized nucleosides, succinates and solid supports of general formula 2 according to claim 5, wherein B is 5-methyl cytosine-N-isobutyryl.

REMARKS

I. Status of the Specification and Claims.

U.S. Patent No. 9,884,885 (“the ‘885 patent”) was issued on February 6, 2018, with claims 1-5. This reissue application pursuant to 35 U.S.C. § 251 corrects at least one error in claiming the invention.

The specification has been amended to correct errors in the printed version of the ‘885 Patent. Certain disclosures in the SUMMARY OF THE INVENTION section on pp. 19-20 of the specification as filed were omitted in columns 17-18 of the printed ‘885 Patent. In addition, the ring structure in Formula 3 at col. 18, ll. 35-45 was printed as a cyclopentane ring instead of the ribose ring as disclosed on p. 20 of the specification as filed.

Claims 1, 4, and 5 have been amended and now have a scope narrower than the scope of originally issued claims 1, 4, and 5. Originally issued claims 2 and 3 have not been amended or canceled, i.e., originally issued claims 2 and 3 remain unchanged from issuance. New claims 6-65 have been added and have a scope narrower than the scope of originally issued claim 1-5. With entry of this Preliminary Amendment, amended claims 1, 4, and 5, originally issued claims 2 and 3, and newly added claims 6-65 are pending in this reissue application. Support for amended claims 1, 4, and 5, and new claims 6-65 is discussed in Part IV of this paper. No new matter has been added and all pending claims satisfy all of the requirements of 35 U.S.C. § 112.

II. Request for Reissue — Statutory Errors.

Only one statutory error is required for reissue. 37 C.F.R. § 1.175(a)(1); M.P.E.P. § 1402. “The reissue error may be directed solely to the failure to previously present narrower claims, which are being added by reissue.” M.P.E.P. § 1402(I).

The '885 patent is wholly or partly inoperative by reason of the patentee claiming less than it had a right to claim in the patent. Specifically, that "claiming less" involved the failure of the patentee to protect the disclosed invention to the full extent allowed by law. *See id.*

In particular, the '885 patentee committed a statutory error under 35 U.S.C. § 251 because the patentee did not present claims that are narrower in scope than the preexisting claims 1-5 and, thus, "claimed less" than it had a right to claim.

The statutory error under 35 U.S.C. § 251 has now been remedied by presently added new claims 6-65.

As set forth in the Reissue Declaration by the Assignee, the '885 patentee confirms that it claimed less than it had a right to claim, at least because the '885 patent failed to previously present narrower claims (necessitating the introduction of new claims 6-65).

For at least the reasons stated above, the issued claims of the '885 patent contained at least one error that rendered the '885 patent partly inoperative.

III. Statement of Status and Support for Specification Changes Pursuant to 37 C.F.R. § 1.173(b)(1).

Applicant has amended the specification to correct errors in the printed version of the '885 Patent. Applicant has amended the specification of the '885 patent to include certain disclosures in the SUMMARY OF THE INVENTION section on pp. 19-20 of the specification as filed, which were omitted in the printed version of the '885 Patent. In addition, the ring structure in Formula 3 in col. 18, ll. 35-45 was printed as a cyclopentane ring instead of the ribose ring as disclosed on p. 20 of the specification as filed. Applicant has amended the structure of Formula 3 to correct this error.

37 C.F.R. § 1.173 (b)(1) reads as follows:

(b) Making amendments in a reissue application. An amendment in a reissue application is made either by physically incorporating the changes into the specification when the application is filed, or by a separate amendment paper. If amendment is made by incorporation, markings pursuant to paragraph (d) of this section must be used. If amendment is made by an amendment paper, the paper must direct that specified changes be made, as follows:

(1) Specification other than the claims. Changes to the specification, other than to the claims, must be made by submission of the entire text of an added or rewritten paragraph, including markings pursuant to paragraph (d) of this section, except that an entire paragraph may be deleted by a statement deleting the paragraph without presentation of the text of the paragraph. The precise point in the specification must be identified where any added or rewritten paragraph is located. This paragraph applies whether the amendment is submitted on paper or compact disc (see §§ 1.52(e)(1) and 1.821(c), but not for discs submitted under § 1.821(e)).

The foregoing amendment to the specification has been made by submission of the entire text of rewritten paragraphs, including markings pursuant to 37 C.F.R. § 1.173 (d). Applicant therefore respectfully submits that the requirements of 37 C.F.R. § 1.173(b) are satisfied.

IV. Statement of Status and Support for Claim Changes Pursuant to 37 C.F.R. § 1.173(c).

37 C.F.R. § 1.173(c) reads as follows:

(c) Status of claims and support for claim changes. Whenever there is an amendment to the claims pursuant to paragraph (b) of this section, there must also be supplied, on pages separate from the pages containing the changes, the status (i.e., pending or canceled), as of the date of the amendment, of all patent claims and of all added claims, and an explanation of the support in the disclosure of the patent for the changes made to the claims.

The status of amended claims 1, 4, and 5, originally issued claims 2 and 3, and newly added claims 6-65 is stated at the beginning of the Remarks above. That statement is on a page separate from the pages of the Preliminary Amendment containing the changes, i.e., the amendment to claims 1, 4, and 5, and the addition of new claims 6-65. Reissue Applicant therefore respectfully submits that the requirements of 37 C.F.R. § 1.173(c) are satisfied.

Reissue Applicant will now explain in detail exemplary support in the disclosure of the '885 patent for amended claims 1, 4, and 5, and new claims 6-65. Hence, there is no written description or enablement issue with any of amended claims 1, 4, and 5, and new claims 6-65. Nor has any new matter been introduced.

The reissue claims are for the same general invention as that disclosed as being the invention in the original patent as required by 35 U.S.C. § 251. As explained in M.P.E.P. § 1412.01, the entire disclosure, not just the claim(s), is considered in determining what the patentee objectively intended as the invention. As detailed below, all of the claims are disclosed as being the invention in the original patent.

Support for the elements of amended claim 1 can be found, *inter alia*, in originally issued claim 1.

Support for the elements of amended claim 4 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of amended claim 5 can be found, *inter alia*, in originally issued claims 3-5 and col. 18, ll. 20-23 of the '885 patent.

Support for the elements of new claim 6 can be found, *inter alia*, in originally issued claim 1.

Support for the elements of new claim 7 can be found, *inter alia*, in originally issued claim 1.

Support for the elements of new claim 8 can be found, *inter alia*, in originally issued claim 1.

Support for the elements of new claim 9 can be found, *inter alia*, in originally issued claim 1.

Support for the elements of new claim 10 can be found, *inter alia*, in originally issued claim 1.

Support for the elements of new claim 11 can be found, *inter alia*, in originally issued claim 2.

Support for the elements of new claim 12 can be found, *inter alia*, in originally issued claim 2.

Support for the elements of new claim 13 can be found, *inter alia*, in originally issued claim 2.

Support for the elements of new claim 14 can be found, *inter alia*, in originally issued claim 2.

Support for the elements of new claim 15 can be found, *inter alia*, in originally issued claim 2.

Support for the elements of new claim 16 can be found, *inter alia*, in originally issued claim 2.

Support for the elements of new claim 17 can be found, *inter alia*, in originally issued claim 2.

Support for the elements of new claim 18 can be found, *inter alia*, in originally issued claim 2.

Support for the elements of new claim 19 can be found, *inter alia*, in originally issued claim 3.

Support for the elements of new claim 20 can be found, *inter alia*, in originally issued claim 3.

Support for the elements of new claim 21 can be found, *inter alia*, in originally issued claim 3.

Support for the elements of new claim 22 can be found, *inter alia*, in originally issued claim 3.

Support for the elements of new claim 23 can be found, *inter alia*, in originally issued claim 3.

Support for the elements of new claim 24 can be found, *inter alia*, in originally issued claim 3.

Support for the elements of new claim 25 can be found, *inter alia*, in originally issued claim 3.

Support for the elements of new claim 26 can be found, *inter alia*, in originally issued claim 3.

Support for the elements of new claim 27 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 28 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 29 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 30 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 31 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 32 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 33 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 34 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 35 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 36 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 37 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 38 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 39 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 40 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 41 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 42 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 43 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 44 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 45 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 46 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 47 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 48 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 49 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 50 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 51 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 52 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 53 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 54 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 55 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 56 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 57 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 58 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 59 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 60 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 61 can be found, *inter alia*, in originally issued claim 4.

Support for the elements of new claim 62 can be found, *inter alia*, in originally issued claim 3-5 and col. 18, ll. 20-23 of the '885 patent.

Support for the elements of new claim 63 can be found, *inter alia*, in originally issued claim 3-5 and col. 18, ll. 20-23 of the '885 patent.

Support for the elements of new claim 64 can be found, *inter alia*, in originally issued claim 3-5 and col. 18, ll. 20-23 of the '885 patent.

Support for the elements of new claim 65 can be found, *inter alia*, in originally issued claim 3-5 and col. 18, ll. 20-23 of the '885 patent.

Thus, the claims presented in the reissue application are described in the original patent specification and enabled by the original patent specification such that 35 U.S.C. § 112, is satisfied. Nothing in the original patent specification indicates an intent not to claim the subject matter of the claims presented in the reissue application. With this amendment, Applicant has amended claims 1, 4, and 5 without prejudice. The status statement is on a page separate from the pages of the Preliminary Amendment containing the changes, i.e., the amendments to the claims. Applicant therefore respectfully submits that the requirements of 37 C.F.R. § 1.173(c) are satisfied.

V. Conclusion.

Reissue Applicant respectfully requests early and favorable consideration of this Preliminary Amendment.

For at least the reasons stated above, Reissue Applicant believes that this reissue application is appropriate and that Reissue Applicant has recited at least one statutory error in conformance with 35 U.S.C. § 251.

Reissue Applicant respectfully submits that the present application is in condition for allowance.

If the Examiner believes, for any reason, that personal communication will expedite prosecution of the application, the Examiner is invited to telephone the undersigned at the number provided. If there are any additional fees associated with the filing of this paper, please charge the same to Deposit Account 02-2135.

Respectfully submitted,

By /Aydin H. Harston/
Aydin H. Harston, Ph.D.
Attorney for Reissue Applicant
Registration No. 65249
ROTHWELL, FIGG, ERNST & MANBECK

Reissue of U.S. Patent No. 9,884,885
Preliminary Amendment

901 New York Avenue, NW, Suite 900 East
Washington, D.C. 20001
Telephone: (202) 783-6040